DDInter1962 DDInter1763
Leukotrienes are substances that induce numerous biological effects including augmentation of neutrophil and eosinophil migration, neutrophil and monocyte aggregation, leukocyte adhesion, increased capillary permeability, and smooth muscle contraction. These effects contribute to inflammation, edema, mucus secretion, and bronchoconstriction in the airways of asthmatic patients. Zileuton relieves such symptoms through its selective inhibition of 5-lipoxygenase, the enzyme that catalyzes the formation of leukotrienes from arachidonic acid. Specifically, it inhibits leukotriene LTB4, LTC4, LTD4, and LTE4 formation. Both the R(+) and S(-) enantiomers are pharmacologically active as 5-lipoxygenase inhibitors in in vitro systems. The immediate release tablet of Zileuton has been withdrawn from the US market.
Temsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel. Temsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007.
Zileuton {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Zileuton {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Temsirolimus
Zileuton {u} (Compound) downregulates {v} (Gene) ZNF395
ZNF395 {u} (Gene) is upregulated by {v} (Compound) Temsirolimus
Zileuton {u} (Compound) causes {v} (Side Effect) Pain
Pain {u} (Side Effect) is caused by {v} (Compound) Temsirolimus
Zileuton {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Everolimus
Everolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Zileuton {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Everolimus
Everolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Zileuton {u} (Compound) downregulates {v} (Gene) ZNF395
ZNF395 {u} (Gene) is regulated by {v} (Gene) HBP1
HBP1 {u} (Gene) is upregulated by {v} (Compound) Temsirolimus
Zileuton {u} (Compound) downregulates {v} (Gene) PLA2G4A
PLA2G4A {u} (Gene) regulates {v} (Gene) TF
TF {u} (Gene) is upregulated by {v} (Compound) Temsirolimus
Zileuton {u} (Compound) causes {v} (Side Effect) Pain
Pain {u} (Side Effect) is caused by {v} (Compound) Everolimus
Everolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Zileuton {u} (Compound) resembles {v} (Compound) Tiaprofenic acid
Tiaprofenic acid {u} (Compound) upregulates {v} (Gene) C5
C5 {u} (Gene) is upregulated by {v} (Compound) Temsirolimus
Zileuton may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Temsirolimus (Compound)
Zileuton (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Temsirolimus (Compound)
Zileuton (Compound) downregulates ZNF395 (Gene) and ZNF395 (Gene) is upregulated by Temsirolimus (Compound)
Zileuton (Compound) causes Pain (Side Effect) and Pain (Side Effect) is caused by Temsirolimus (Compound)
Zileuton may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Everolimus (Compound) and Everolimus (Compound) resembles Temsirolimus (Compound)
Zileuton (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Everolimus (Compound) and Everolimus (Compound) resembles Temsirolimus (Compound)
Zileuton (Compound) downregulates ZNF395 (Gene) and ZNF395 (Gene) is regulated by HBP1 (Gene) and HBP1 (Gene) is upregulated by Temsirolimus (Compound)
Zileuton (Compound) downregulates PLA2G4A (Gene) and PLA2G4A (Gene) regulates TF (Gene) and TF (Gene) is upregulated by Temsirolimus (Compound)
Zileuton (Compound) causes Pain (Side Effect) and Pain (Side Effect) is caused by Everolimus (Compound) and Everolimus (Compound) resembles Temsirolimus (Compound)
Zileuton (Compound) resembles Tiaprofenic acid (Compound) and Tiaprofenic acid (Compound) upregulates C5 (Gene) and C5 (Gene) is upregulated by Temsirolimus (Compound)